Coherus Oncology, Inc. (CHRS) Operating income 2016–2025
Coherus Oncology, Inc. (CHRS) annual operating income history from SEC filings — each fiscal year as reported.
-$181.1MFY2025 · since FY2016: -$115.9M → -$181.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$181.1M | +9.3% |
| FY2024 | -$199.7M | +7.5% |
| FY2023 | -$215.8M | +16.0% |
| FY2022 | -$256.9M | +2.6% |
| FY2021 | -$263.9M | -268.8% |
| FY2020 | $156.3M | +45.1% |
| FY2019 | $107.8M | +152.7% |
| FY2018 | -$204.4M | +11.9% |
| FY2017 | -$232.1M | -100.2% |
| FY2016 | -$115.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice